Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 3/20 | 0.43 |
| ▸ | FNTB | P49356 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051376 | 1.00 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL1983976 | 1.00 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL28767097 | 0.98 | KDM4E (0.55) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL929660 | 0.92 | ACE (0.55) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Cysteine SCHEMBL27656948 | 0.91 | PTGS1 (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL29702215 | 0.88 | ACE (0.50) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL7790449 | 0.87 | KDM4E (0.48) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL7790453 | 0.87 | KDM4E (0.48) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL29567569 | 0.86 | PTGS1 (0.54) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL25774753 | 0.86 | ACE (0.49) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4627103-A1 | IMPEDIMETRIC DETECTION USING PEPTIDE AND PEPTIDE MIXTURES | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2025-10-08 | — | — | EP | claimed |
| EP-4536265-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Jenius Pharma, LLC (US) | 2025-04-16 | — | — | EP | claimed |
| US-12129277-B2 | Linear solution phase routes for WNT hexapeptides | WNTRESEARCH AB (SE) | 2024-10-29 | — | — | US | claimed |
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | claimed |
| WO-2024116168-A1 | IMPEDIMETRIC DETECTION USING PEPTIDE AND PEPTIDE MIXTURES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-06-06 | — | — | WO | claimed |
| CN-113646324-B | Linear solution phase pathway for WNT hexapeptide | 温特研究公司 | 2024-03-29 | — | — | CN | claimed |
| US-20240101714-A1 | ASSEMBLY OF BISPECIFIC ANTIBODIES | GENENTECH INC (US) | 2024-03-28 | — | — | US | claimed |
| CN-111285921-B | BDK auxiliary group and liquid phase total synthesis method of procalcitonin and analog based on BDK auxiliary group | 西北工业大学 | 2024-03-01 | — | — | CN | claimed |
| US-11912791-B2 | Solution phase routes for Wnt hexapeptides | WNTRESEARCH AB (SE) | 2024-02-27 | — | — | US | claimed |
| WO-2023239716-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC (US) | 2023-12-14 | — | — | WO | claimed |
| EP-0565862-B1 | Semi-synthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN SPA (IT) | 1997-06-18 | — | — | EP | claimed |
| EP-0618234-B1 | Process for the synthesis of semisynthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-0-sulfate acid | ALFA WASSERMANN SPA (IT) | 1997-06-04 | — | — | EP | claimed |
| US-5635170-A | N-GLYCINE-L-CYSTEINE AND/OR L-CYSTEINE-N-GLYCINE IS USED AS HAIR KERATIN REDUCING AGENT | WELLA AKTIENGESELLCHAFT (DE) | 1997-06-03 | — | — | US | claimed |
| US-5430133-A | Semi-synthetic glycosaminoglycans with heparin or heparan structure of α-L-iduronic-2-O-sulfate acid modified in position 2 | ALFA WASSERMANN S.P.A. (IT) | 1995-07-04 | — | — | US | claimed |
| US-5410039-A | Process for the synthesis of glycosaminoglycans containing α-L-galacturonic acid substituted with nucleophilic groups in position 3 | ALFA WASSERMANN S.P.A. (IT) | 1995-04-25 | — | — | US | claimed |
| US-5405949-A | Process for the synthesis of glycosaminoglycans with heparin or heparan structure modified in position 2 of the α-L-iduronic-2-O-sulfate acid | ALFA WASSERNANN S.P.A. (IT) | 1995-04-11 | — | — | US | claimed |
| EP-0618235-A1 | Process for the synthesis of semisynthetic glycosaminoglycans containig alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0618234-A1 | Process for the synthesis of semisynthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-0-sulfate acid | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0565863-A2 | Semi-synthetic glycosaminoglycans with heparin or heparan structure of alpha-L-iduronic-2-0-sulfate acid modified in position 2 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |
| EP-0565862-A2 | Semi-synthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |